Currently, adalimumab (otherwise known as Humira) is the representative TNF-α blocker for the treatment of rheumatoid arthritis (RA) and other common inflammatory arthropathies (Furst et al. 2007; Nasonov 2007). The gene discussed is TNF; the disease is rheumatoid arthritis.